Caris Life Sciences (NASDAQ:CAI) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Caris Life Sciences (NASDAQ:CAI) from a hold rating to a buy rating in a research report released on Saturday morning.

CAI has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group increased their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Finally, Evercore ISI set a $38.00 target price on shares of Caris Life Sciences in a report on Monday, January 5th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Caris Life Sciences currently has a consensus rating of “Reduce” and a consensus target price of $34.00.

Caris Life Sciences Price Performance

CAI stock opened at $26.78 on Friday. The stock has a market cap of $7.56 billion and a price-to-earnings ratio of -58.22. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. Caris Life Sciences has a 12-month low of $22.86 and a 12-month high of $42.50.

Insider Activity at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider directly owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

A number of institutional investors have recently added to or reduced their stakes in the company. Zevenbergen Capital Investments LLC acquired a new stake in shares of Caris Life Sciences during the fourth quarter valued at about $14,655,000. Diversified Trust Co. purchased a new position in Caris Life Sciences in the fourth quarter valued at about $540,000. Finally, Olistico Wealth LLC acquired a new stake in Caris Life Sciences during the 4th quarter valued at approximately $31,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.